125 related articles for article (PubMed ID: 36854309)
1. Locoregional Treatment of Glioblastoma With Targeted α Therapy: [ 213 Bi]Bi-DOTA-Substance P Versus [ 225 Ac]Ac-DOTA-Substance P-Analysis of Influence Parameters.
Królicki L; Kunikowska J; Bruchertseifer F; Kuliński R; Pawlak D; Koziara H; Rola R; Morgenstern A; Merlo A
Clin Nucl Med; 2023 May; 48(5):387-392. PubMed ID: 36854309
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation study of targeted alpha therapy with [
Królicki L; Bruchertseifer F; Kunikowska J; Koziara H; Pawlak D; Kuliński R; Rola R; Merlo A; Morgenstern A
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3595-3605. PubMed ID: 33860346
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of targeted alpha therapy with
Królicki L; Bruchertseifer F; Kunikowska J; Koziara H; Królicki B; Jakuciński M; Pawlak D; Apostolidis C; Mirzadeh S; Rola R; Merlo A; Morgenstern A
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):614-622. PubMed ID: 30498897
[TBL] [Abstract][Full Text] [Related]
4. Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with
Krolicki L; Bruchertseifer F; Kunikowska J; Koziara H; Królicki B; Jakuciński M; Pawlak D; Apostolidis C; Mirzadeh S; Rola R; Merlo A; Morgenstern A
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1636-1644. PubMed ID: 29713762
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of
Majkowska-Pilip A; Rius M; Bruchertseifer F; Apostolidis C; Weis M; Bonelli M; Laurenza M; Królicki L; Morgenstern A
Chem Biol Drug Des; 2018 Jul; 92(1):1344-1356. PubMed ID: 29611298
[TBL] [Abstract][Full Text] [Related]
6. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial.
Cordier D; Forrer F; Bruchertseifer F; Morgenstern A; Apostolidis C; Good S; Müller-Brand J; Mäcke H; Reubi JC; Merlo A
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1335-44. PubMed ID: 20157707
[TBL] [Abstract][Full Text] [Related]
7. Targeted alpha therapy for glioblastoma.
Kunikowska J; Morgenstern A; Pełka K; Bruchertseifer F; Królicki L
Front Med (Lausanne); 2022; 9():1085245. PubMed ID: 36590948
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?
Krolicki L; Kunikowska J; Cordier D; Slavova N; Koziara H; Bruchertseifer F; Maecke HR; Morgenstern A; Merlo A
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958683
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I study.
Cordier D; Forrer F; Kneifel S; Sailer M; Mariani L; Mäcke H; Müller-Brand J; Merlo A
J Neurooncol; 2010 Oct; 100(1):129-36. PubMed ID: 20217458
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.
Essler M; Gärtner FC; Neff F; Blechert B; Senekowitsch-Schmidtke R; Bruchertseifer F; Morgenstern A; Seidl C
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):602-12. PubMed ID: 22237842
[TBL] [Abstract][Full Text] [Related]
11. Vascular architecture mapping for early detection of glioblastoma recurrence.
Stadlbauer A; Eyüpoglu I; Buchfelder M; Dörfler A; Zimmermann M; Heinz G; Oberndorfer S
Neurosurg Focus; 2019 Dec; 47(6):E14. PubMed ID: 31786560
[TBL] [Abstract][Full Text] [Related]
12.
Królicki L; Kunikowska J; Bruchertseifer F; Koziara H; Królicki B; Jakuciński M; Pawlak D; Rola R; Morgenstern A; Rosiak E; Merlo A
Semin Nucl Med; 2020 Mar; 50(2):141-151. PubMed ID: 32172799
[TBL] [Abstract][Full Text] [Related]
13. Second-Line Chemotherapy in Recurrent Glioblastoma: A 2-Cohort Study.
Carvalho BF; Fernandes AC; Almeida DS; Sampaio LV; Costa A; Caeiro C; Osório L; Castro L; Linhares P; Damasceno M; Vaz RC
Oncol Res Treat; 2015; 38(7-8):348-54. PubMed ID: 26278578
[TBL] [Abstract][Full Text] [Related]
14. Towards Facile Radiolabeling and Preparation of Gallium-68-/Bismuth-213-DOTA-[Thi
Suthiram J; Ebenhan T; Marjanovic-Painter B; Sathekge MM; Zeevaart JR
Pharmaceutics; 2021 Aug; 13(9):. PubMed ID: 34575402
[TBL] [Abstract][Full Text] [Related]
15. Tachykinin Receptor-Selectivity of the Potential Glioblastoma-Targeted Therapy, DOTA-[Thi
Suthiram J; Pieters A; Mohamed Moosa Z; Zeevaart JR; Sathekge MM; Ebenhan T; Anderson RC; Newton CL
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768456
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
[No Abstract] [Full Text] [Related]
17. Long-Term Results of Targeted Low-Grade Glioma Treatment with
Cordier D; Merlo A
Cancer Biother Radiopharm; 2019 Aug; 34(6):413-416. PubMed ID: 30844298
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
19. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
[TBL] [Abstract][Full Text] [Related]
20. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
